Home › Funds › ELKHORN PARTNERS LIMITED PARTNERSHIP › BHVN
ELKHORN PARTNERS LIMITED PARTNERSHIP position in BHVN
BIOHAVEN LTD · Health Care
ELKHORN PARTNERS LIMITED PARTNERSHIP reported holding 300 shares of BHVN (BIOHAVEN LTD) in its Q3 2026 13F filing — a position valued at US$4K, representing 0.00% of its reported portfolio and ranking #48 among its reported holdings. ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed BHVN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ELKHORN PARTNERS LIMITED PARTNERSHIP's BHVN position evolved
ELKHORN PARTNERS LIMITED PARTNERSHIP first disclosed a stake in BHVN in Q2 2024 at 3,600 shares (US$125K). Across 10 filings, ELKHORN PARTNERS LIMITED PARTNERSHIP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 300 shares valued at US$4K — a reduction of -800 shares quarter over quarter.. Notable position changes include a 50% increase in Q4 2024 (shares fell 36% over the following quarter), a 75% trim in Q4 2025 (shares fell 25% over the following quarter), a 73% trim in Q3 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 3.60K | $125.00K | New |
| Q3 2024 | 2.20K | $110.00K | Reduce |
| Q4 2024 | 3.30K | $123.00K | Add |
| Q1 2025 | 4.60K | $111.00K | Add |
| Q2 2025 | 5.80K | $81.84K | Add |
| Q3 2025 | 5.90K | $88.56K | Add |
| Q4 2025 | 1.50K | $16.93K | Reduce |
| Q1 2026 | 2.00K | $16.92K | Add |
| Q2 2026 | 1.10K | $16.37K | Reduce |
| Q3 2026 | 300 | $4.00K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BHVN and 13F data
BHVN (BIOHAVEN LTD) is a Health Care company. 27 other funds we track also report a position in BHVN — the largest reported positions include MONTANOVA CAPITAL, LLC (US$153.1M), INFINITUM ASSET MANAGEMENT, LLC (US$93.0M), Royalty Pharma Sub-Manager, LLC (US$43.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BHVN
- MONTANOVA CAPITAL, LLC 10.29M sh · $153.07M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 6.25M sh · $93.00M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.94M sh · $43.70M · Q2 2026
- Cormorant Asset Management, LP 2.61M sh · $38.84M · Q2 2026
- Knoll Capital Management, LLC 2.35M sh · $35.01M · Q2 2026
- TCG Crossover Management, LLC 1.78M sh · $26.49M · Q2 2026
More on ELKHORN PARTNERS LIMITED PARTNERSHIP
FAQ
How long has ELKHORN PARTNERS LIMITED PARTNERSHIP held BHVN?
ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed BHVN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is ELKHORN PARTNERS LIMITED PARTNERSHIP's current position in BHVN?
As of Q3 2026, ELKHORN PARTNERS LIMITED PARTNERSHIP holds 300 shares of BHVN (BIOHAVEN LTD), valued at $4.00K, representing 0.00% of its reported portfolio and ranking #48.
Has ELKHORN PARTNERS LIMITED PARTNERSHIP been buying or selling BHVN?
In the latest 13F filing (Q3 2026), ELKHORN PARTNERS LIMITED PARTNERSHIP reduced its position in BHVN.
Which other funds hold BHVN?
Other major institutional holders of BHVN include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Royalty Pharma Sub-Manager, LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.